BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38170337)

  • 1. Interferon-Gamma-Inducible Protein 16 Inhibits Hepatocellular Carcinoma via Interferon Regulatory Factor 3 on Chemosensitivity.
    Lin W; Zhao Z; Du W; Ni Z; Pan C; Fang P; Li J; ZhuGe L; Jin S
    Dig Dis Sci; 2024 Feb; 69(2):491-501. PubMed ID: 38170337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exosomes function as nanoparticles to transfer miR-199a-3p to reverse chemoresistance to cisplatin in hepatocellular carcinoma.
    Zhang K; Shao CX; Zhu JD; Lv XL; Tu CY; Jiang C; Shang MJ
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32463473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of
    Liu Z; Dang C; Xing E; Zhao M; Shi L; Sun J
    DNA Cell Biol; 2019 Nov; 38(11):1366-1373. PubMed ID: 31633393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial fission factor promotes cisplatin resistancein hepatocellular carcinoma.
    Li X; Wu Q; Ma F; Zhang X; Cai L; Yang X
    Acta Biochim Biophys Sin (Shanghai); 2022 Mar; 54(3):301-310. PubMed ID: 35538029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long non-coding RNA FGD5-AS1 contributes to cisplatin resistance in hepatocellular carcinoma via sponging microRNA-153-3p by upregulating Twinfilin Actin Binding Protein 1 (TWF1).
    Yang Y; Shi L; Zhang D; Wu D; An Y; Zhang Y; Chen X
    Bioengineered; 2021 Dec; 12(1):6713-6723. PubMed ID: 34519634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of Linc00173 increases BCL2 mRNA stability via the miR-1275/PROCA1/ZFP36L2 axis and induces acquired cisplatin resistance of lung adenocarcinoma.
    Tao X; Li Y; Fan S; Wu L; Xin J; Su Y; Xian X; Huang Y; Huang R; Fang W; Liu Z
    J Exp Clin Cancer Res; 2023 Jan; 42(1):12. PubMed ID: 36627670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long noncoding RNA LEF1-AS1 acts as a microRNA-10a-5p regulator to enhance MSI1 expression and promote chemoresistance in hepatocellular carcinoma cells through activating AKT signaling pathway.
    Gao J; Dai C; Yu X; Yin XB; Zhou F
    J Cell Biochem; 2021 Jan; 122(1):86-99. PubMed ID: 32786108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
    Xiao XH; He SY
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of lncRNA KCNQ1OT1 on autophagy and drug resistance of hepatocellular carcinoma cells by targeting miR-338-3p.
    Zhong W; Dai Q; Huang Q
    Cell Mol Biol (Noisy-le-grand); 2020 Jun; 66(3):191-196. PubMed ID: 32538770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer-associated fibroblast exosomes promote chemoresistance to cisplatin in hepatocellular carcinoma through circZFR targeting signal transducers and activators of transcription (STAT3)/ nuclear factor -kappa B (NF-κB) pathway.
    Zhou Y; Tang W; Zhuo H; Zhu D; Rong D; Sun J; Song J
    Bioengineered; 2022 Mar; 13(3):4786-4797. PubMed ID: 35139763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silencing of miR-1246 Induces Cell Cycle Arrest and Apoptosis in Cisplatin-Resistant Ovarian Cancer Cells by Promoting ZNF23 Transcription.
    Cai L; Zhang Q; Du L; Zheng F
    Cytogenet Genome Res; 2021; 161(10-11):488-500. PubMed ID: 34923485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-21-5p Suppressed the Sensitivity of Hepatocellular Carcinoma Cells to Cisplatin by Targeting FASLG.
    Chen S; Yang C; Sun C; Sun Y; Yang Z; Cheng S; Zhuge B
    DNA Cell Biol; 2019 Aug; 38(8):865-873. PubMed ID: 31225740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA FAM13A-AS1, transcriptionally regulated by PHOX2B, modulates hepatocellular carcinoma chemoresistance via stabilizing PPARγ.
    Ye D; Ma J; Yu T; Ran F; Zha Y
    Gene; 2023 Aug; 877():147570. PubMed ID: 37330023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IFI16 restoration in hepatocellular carcinoma induces tumour inhibition via activation of p53 signals and inflammasome.
    Lin W; Zhao Z; Ni Z; Zhao Y; Du W; Chen S
    Cell Prolif; 2017 Dec; 50(6):. PubMed ID: 28990231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nutlin-3-induced redistribution of chromatin-bound IFI16 in human hepatocellular carcinoma cells in vitro is associated with p53 activation.
    Shi XL; Yang J; Mao N; Wu JH; Ren LF; Yang Y; Yin XL; Wei L; Li MY; Wang BN
    Acta Pharmacol Sin; 2015 Feb; 36(2):252-8. PubMed ID: 25544361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma and increases the sensitivity to cisplatin.
    Cai S; Bai Y; Wang H; Zhao Z; Ding X; Zhang H; Zhang X; Liu Y; Jia Y; Li Y; Chen S; Zhou H; Liu H; Yang C; Sun T
    J Exp Clin Cancer Res; 2020 Jul; 39(1):135. PubMed ID: 32669125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low‑intensity ultrasound enhances the chemosensitivity of hepatocellular carcinoma cells to cisplatin via altering the miR‑34a/c‑Met axis.
    Li P; Zhang J; Li F; Yu Y; Chen Y
    Int J Mol Med; 2019 Jul; 44(1):135-144. PubMed ID: 31115495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-183 overexpression inhibits tumorigenesis and enhances DDP-induced cytotoxicity by targeting MTA1 in nasopharyngeal carcinoma.
    Wang G; Wang S; Li C
    Tumour Biol; 2017 Jun; 39(6):1010428317703825. PubMed ID: 28631568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. circ-LDLRAD3 Knockdown Reduces Cisplatin Chemoresistance and Inhibits the Development of Gastric Cancer with Cisplatin Resistance through miR-588 Enrichment-Mediated SOX5 Inhibition.
    Liang Q; Chu F; Zhang L; Jiang Y; Li L; Wu H
    Gut Liver; 2023 May; 17(3):389-403. PubMed ID: 35975639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
    Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY
    Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.